Below is a detailed analysis of the quarterly data for Wockhardt Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 743.00 Cr.. The value appears strong and on an upward trend. It has increased from 721.00 Cr. (Dec 2024) to 743.00 Cr., marking an increase of 22.00 Cr..
For Expenses, as of Mar 2025, the value is 679.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 593.00 Cr. (Dec 2024) to 679.00 Cr., marking an increase of 86.00 Cr..
For Operating Profit, as of Mar 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Dec 2024) to 64.00 Cr., marking a decrease of 64.00 Cr..
For OPM %, as of Mar 2025, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Dec 2024) to 9.00%, marking a decrease of 9.00%.
For Other Income, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Dec 2024) to 15.00 Cr., marking an increase of 7.00 Cr..
For Interest, as of Mar 2025, the value is 48.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 60.00 Cr. (Dec 2024) to 48.00 Cr., marking a decrease of 12.00 Cr..
For Depreciation, as of Mar 2025, the value is 53.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 55.00 Cr. (Dec 2024) to 53.00 Cr., marking a decrease of 2.00 Cr..
For Profit before tax, as of Mar 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Dec 2024) to -22.00 Cr., marking a decrease of 43.00 Cr..
For Tax %, as of Mar 2025, the value is 105.00%. The value appears to be increasing, which may not be favorable. It has increased from 5.00% (Dec 2024) to 105.00%, marking an increase of 100.00%.
For Net Profit, as of Mar 2025, the value is -45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Dec 2024) to -45.00 Cr., marking a decrease of 65.00 Cr..
For EPS in Rs, as of Mar 2025, the value is -1.54. The value appears to be declining and may need further review. It has decreased from 0.86 (Dec 2024) to -1.54, marking a decrease of 2.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:24 pm
Metric
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
4,830
4,482
4,453
4,015
3,937
3,566
2,844
2,708
3,230
2,651
2,798
3,012
Expenses
3,805
3,772
3,959
4,002
3,935
3,604
2,725
2,771
2,932
2,549
2,707
2,619
Operating Profit
1,026
709
494
13
2
-38
119
-63
298
102
91
393
OPM %
21%
16%
11%
0%
0%
-1%
4%
-2%
9%
4%
3%
13%
Other Income
88
67
66
114
-238
116
133
975
-163
-173
17
62
Interest
83
55
129
225
255
265
276
249
299
302
305
254
Depreciation
140
145
142
149
150
164
224
246
247
251
223
217
Profit before tax
891
575
289
-247
-641
-351
-247
417
-411
-624
-420
-16
Tax %
5%
28%
13%
-9%
4%
-38%
-82%
-65%
-32%
-0%
12%
256%
Net Profit
843
413
252
-226
-667
-217
-43
688
-279
-621
-472
-57
EPS in Rs
58.91
28.30
17.45
-13.62
-42.30
-13.52
-4.81
47.64
-16.94
-38.80
-30.18
-2.89
Dividend Payout %
13%
54%
0%
-56%
0%
0%
0%
0%
0%
0%
0%
0%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
-51.01%
-38.98%
-189.68%
-195.13%
67.47%
80.18%
1700.00%
-140.55%
-122.58%
23.99%
87.92%
Change in YoY Net Profit Growth (%)
0.00%
12.03%
-150.70%
-5.45%
262.60%
12.72%
1619.82%
-1840.55%
17.97%
146.57%
63.93%
Wockhardt Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
-4%
5 Years:
1%
3 Years:
-2%
TTM:
8%
Compounded Profit Growth
10 Years:
%
5 Years:
-2%
3 Years:
15%
TTM:
88%
Stock Price CAGR
10 Years:
3%
5 Years:
46%
3 Years:
102%
1 Year:
150%
Return on Equity
10 Years:
-2%
5 Years:
0%
3 Years:
-7%
Last Year:
-1%
Last Updated: Unknown
No data available for the Balance Sheet data table.
After reviewing the key financial ratios for Wockhardt Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
For Diluted EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
For Cash EPS (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has increased from -16.17 (Mar 24) to 9.88, marking an increase of 26.05.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 185.93. It has increased from 181.69 (Mar 24) to 185.93, marking an increase of 4.24.
For PBDIT / Share (Rs.), as of Mar 25, the value is 28.09. This value is within the healthy range. It has increased from 7.92 (Mar 24) to 28.09, marking an increase of 20.17.
For PBIT / Share (Rs.), as of Mar 25, the value is 14.69. This value is within the healthy range. It has increased from -6.56 (Mar 24) to 14.69, marking an increase of 21.25.
For PBT / Share (Rs.), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 0. It has increased from -27.27 (Mar 24) to -0.98, marking an increase of 26.29.
For Net Profit / Share (Rs.), as of Mar 25, the value is -3.52. This value is below the healthy minimum of 2. It has increased from -30.65 (Mar 24) to -3.52, marking an increase of 27.13.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.90. This value is below the healthy minimum of 2. It has increased from -30.06 (Mar 24) to -2.90, marking an increase of 27.16.
For PBDIT Margin (%), as of Mar 25, the value is 15.10. This value is within the healthy range. It has increased from 4.36 (Mar 24) to 15.10, marking an increase of 10.74.
For PBIT Margin (%), as of Mar 25, the value is 7.90. This value is below the healthy minimum of 10. It has increased from -3.60 (Mar 24) to 7.90, marking an increase of 11.50.
For PBT Margin (%), as of Mar 25, the value is -0.53. This value is below the healthy minimum of 10. It has increased from -15.01 (Mar 24) to -0.53, marking an increase of 14.48.
For Net Profit Margin (%), as of Mar 25, the value is -1.89. This value is below the healthy minimum of 5. It has increased from -16.86 (Mar 24) to -1.89, marking an increase of 14.97.
For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.56. This value is below the healthy minimum of 8. It has increased from -16.54 (Mar 24) to -1.56, marking an increase of 14.98.
For Return on Networth / Equity (%), as of Mar 25, the value is -1.07. This value is below the healthy minimum of 15. It has increased from -13.78 (Mar 24) to -1.07, marking an increase of 12.71.
For Return on Capital Employeed (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 3.90, marking an increase of 5.97.
For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has increased from -6.05 (Mar 24) to -0.57, marking an increase of 5.48.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has increased from 0.26 (Mar 24) to 0.27, marking an increase of 0.01.
For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has increased from 0.36 (Mar 24) to 0.38, marking an increase of 0.02.
For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has increased from 0.78 (Mar 24) to 1.26, marking an increase of 0.48.
For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.55 (Mar 24) to 0.90, marking an increase of 0.35.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 4. It has decreased from 0.95 (Mar 24) to 0.89, marking a decrease of 0.06.
For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 0.40 (Mar 24) to 1.79, marking an increase of 1.39.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 3. It has increased from -0.50 (Mar 24) to 0.77, marking an increase of 1.27.
For Enterprise Value (Cr.), as of Mar 25, the value is 25,036.75. It has increased from 10,872.67 (Mar 24) to 25,036.75, marking an increase of 14,164.08.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.31. This value exceeds the healthy maximum of 3. It has increased from 3.89 (Mar 24) to 8.31, marking an increase of 4.42.
For EV / EBITDA (X), as of Mar 25, the value is 55.03. This value exceeds the healthy maximum of 15. It has decreased from 89.12 (Mar 24) to 55.03, marking a decrease of 34.09.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
For Price / BV (X), as of Mar 25, the value is 5.30. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 5.30, marking an increase of 2.62.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.00, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Wockhardt Ltd as of June 30, 2025 is: 40.02
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 30, 2025, Wockhardt Ltd is Overvalued by 97.67% compared to the current share price 1,716.00
Default values used*: Default value of 15 for Stock P/E is used
Intrinsic Value of Wockhardt Ltd as of June 30, 2025 is: 18.19
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 30, 2025, Wockhardt Ltd is Overvalued by 98.94% compared to the current share price 1,716.00
Default values used*: Default value of 15 for Stock P/E is used
Last 5 Year EPS CAGR: -54.54%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Wockhardt Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: -1.07% (Industry Average ROE: 15.19%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 0 (Industry average Stock P/E: 101.91)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.42
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Wockhardt Ltd. is a Public Limited Listed company incorporated on 08/07/1999 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1999PLC120720 and registration number is 120720. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1402.00 Cr. and Equity Capital is Rs. 81.00 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Wockhardt Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
